Navigation Links
Penn researchers use honeybee venom toxin to develop a new tool for studying hypertension
Date:9/17/2008

PHILADELPHIA - Researchers at the University of Pennsylvania School of Medicine have modified a honeybee venom toxin so that it can be used as a tool to study the inner workings of ion channels that control heart rate and the recycling of salt in kidneys. In general, ion channels selectively allow the passage of small ions such as sodium, potassium, or calcium into and out of the cell.

The study, published in the Proceedings of the National Academy of Sciences, is from the laboratory of Zhe Lu, M.D, Ph.D., Professor of Physiology and a Howard Hughes Medical Institute Investigator, who looked at the action of a natural bee toxin on inward-rectifier potassium channels, Kir channels for short, to identify new approaches to treat cardiovascular disease.

The honeybee venom toxin, called tertiapin, or TPN, stops the flow of potassium ions across cell membranes by plugging up the opening of Kir channels on the outside of cells. Kir channels in kidneys are potential new targets for treating hypertension. "The clue comes from patients with genetic defects in these channels who lose a lot of sodium because it cannot be effectively reabsorbed and thus have low blood pressure," notes Lu. "An inhibitor specifically against these kidney channels will allow this idea to be tested."

Developing a specific inhibitor for one type of Kir channel has been challenging because the target site is very similar among different types of Kir channels. For example, while TPN inhibits Kir type 1 channels in kidney cells, it also inhibits other types of Kir channels in heart cells. After more than a decade, Lu and his colleagues succeeded in bioengineering a TPN that selectively inhibits Kir channels important for salt recycling in kidneys.

By introducing two mutations into TPN, they engineered a variant, called TPNLQ, which stems the flow of potassium ions in renal Kir type 1 channels at low concentrations, and with a 250-fold sensitivity over six other types of Kir channels.

The development of TPNLQ demonstrates that a highly specific inhibitor of potassium channels can be engineered. TPNLQ can now be used as a tool to prove the concept, in animal studies, that reducing salt reabsorption by plugging up renal Kir type 1 potassium channels is a potential new way to treat hypertension.


'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Johns Hopkins researchers suppress hunger hormone
2. Penn researchers identify natural tumor suppressor
3. Two U.S. Researchers Win Prestigious International Science Award
4. Researchers receive grant to study ways of preventing heart disease
5. Yerkes researchers create animal model of chronic stress
6. Surgical technique halts cell loss, Parkinsons researchers find
7. Millions face undiagnosed heart risk say researchers after mass screening
8. Superbug breast infections controllable in nursing mothers, UT Southwestern researchers find
9. Heart attack patients who stop statin risk death, say McGill researchers
10. UTMB researchers test new vaccine to fight multiple influenza strains
11. New method to overcome multiple drug resistant diseases developed by Stanford researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... ... environs, is proud to announce an upgrade to the company's Yelp listing. Bay ... page on topics as diverse as Platelet Rich Plasma (PRP) therapy, hair transplantation ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... the lab became the world’s first to be ISO/IEC 17025:2005 INAB accredited for ... analysis. , ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... scheduling, and reporting for healthcare organizations. This comprehensive and customizable solution empowers ... process. StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects critical reporting ...
(Date:2/25/2017)... ... February 25, 2017 , ... FCPX users now have the ... Pixel Film Studios. With ProSharpen Color users have total control over sharpening amount, sharpening ... color range. With color spectrum tools users can visually see the color range effected ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... education, networking and recognition opportunities as well as advocacy for the state and ... NJ on February 23. The Council's Innovation Forecast event highlights innovation throughout ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Mass. , Feb. 27, 2017  Infinity Pharmaceuticals, ... at the Cowen and Company 37 th Annual ... p.m. ET in Boston, MA. ... on the Investors/Media section of Infinity,s website at ... following the event. About Infinity,Infinity is an ...
(Date:2/27/2017)... , Feb. 27, 2017  Impax Laboratories, Inc. (NASDAQ: IPXL ) ... conferences. Raymond James and Associates, 38 ... 6, 2017 in Orlando, FL. ... a.m. ET on March 7, 2017 in Boston, MA. ... March 16, 2017 in Miami, FL. ...
(Date:2/27/2017)... February 27, 2017 A recent research report ... marijuana market alone is expected to reach a value of $55.8 ... along with 28 states have legalized marijuana for medical uses. ... Florida , North Dakota , ... approved to use the drug in medical applications such as chemotherapies ...
Breaking Medicine Technology: